Finance

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

By ThePostMasterJune 1, 2025No Comments1 Min Read

$Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML$

ThePostMaster

Add A Comment

What's Hot

Japan's ex-top FX diplomat expects yen to rise near 140 by year-end

Guess the Sauna Star Breakin’ a Sweat!

Retest of the 200-Day Moving Average Isn’t Bearish—Unless It Fails

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

HSBC picks Nelson as interim chair

230%+ gains in the bank: check out our AI’s top picks for June now

Mets vs. Dodgers odds, prediction, props: Proven model’s free 2025 MLB picks, Tuesday, June 3 best bets

MLB insider’s trade deadline picks include Red Sox, Marlins surprises

Queen Elizabeth the Last! Monarchy Faces Fresh Demand to be Axed

Which Airlines are Best Following COVID-19 Safety Protocols

Future Queen of Spain to Attend ‘Finishing School for Royals’

What's Hot

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Kura Oncology and Kyowa Kirin Announce FDA Acceptance and Priority Review of New Drug Application for Ziftomenib in Adults with Relapsed or Refractory NPM1-Mutant AML

Subscribe to Updates